Additionally, SATB1 silencing using RNA interference techniques, including siRNA and shRNA, has demonstrated the ability to inhibit tumor cell proliferation and invasion in preclinical models (23, 26, 33, 102, 103), positioning SATB1 as a promising therapeutic target. The gene discussed is SATB1; the disease is neoplasm.